1. Home
  2. SLS vs CURR Comparison

SLS vs CURR Comparison

Compare SLS & CURR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLS
  • CURR
  • Stock Information
  • Founded
  • SLS 2012
  • CURR 2013
  • Country
  • SLS United States
  • CURR Singapore
  • Employees
  • SLS N/A
  • CURR N/A
  • Industry
  • SLS Biotechnology: Pharmaceutical Preparations
  • CURR Business Services
  • Sector
  • SLS Health Care
  • CURR Consumer Discretionary
  • Exchange
  • SLS Nasdaq
  • CURR Nasdaq
  • Market Cap
  • SLS 238.7M
  • CURR 224.4M
  • IPO Year
  • SLS N/A
  • CURR N/A
  • Fundamental
  • Price
  • SLS $1.51
  • CURR $3.43
  • Analyst Decision
  • SLS Strong Buy
  • CURR Strong Buy
  • Analyst Count
  • SLS 1
  • CURR 1
  • Target Price
  • SLS $7.00
  • CURR $3.50
  • AVG Volume (30 Days)
  • SLS 5.3M
  • CURR 2.2M
  • Earning Date
  • SLS 11-07-2025
  • CURR 11-01-2025
  • Dividend Yield
  • SLS N/A
  • CURR N/A
  • EPS Growth
  • SLS N/A
  • CURR N/A
  • EPS
  • SLS N/A
  • CURR N/A
  • Revenue
  • SLS N/A
  • CURR $41,092,419.00
  • Revenue This Year
  • SLS N/A
  • CURR N/A
  • Revenue Next Year
  • SLS N/A
  • CURR $14.56
  • P/E Ratio
  • SLS N/A
  • CURR N/A
  • Revenue Growth
  • SLS N/A
  • CURR N/A
  • 52 Week Low
  • SLS $0.77
  • CURR $0.33
  • 52 Week High
  • SLS $2.48
  • CURR $7.08
  • Technical
  • Relative Strength Index (RSI)
  • SLS 32.03
  • CURR 66.36
  • Support Level
  • SLS $1.85
  • CURR $1.69
  • Resistance Level
  • SLS $2.06
  • CURR $4.68
  • Average True Range (ATR)
  • SLS 0.14
  • CURR 0.65
  • MACD
  • SLS -0.06
  • CURR 0.12
  • Stochastic Oscillator
  • SLS 0.00
  • CURR 60.06

About SLS SELLAS Life Sciences Group Inc.

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

About CURR Currenc Group Inc. Ordinary Shares

Currenc Group Inc is a fintech pioneer dedicated to transforming financial services through artificial intelligence (AI). It empowers financial institutions with comprehensive AI solutions, including the SEAMLESS AI Call Centre and other AI-powered tools designed to reduce costs, increase efficiency, and boost customer satisfaction. The Company's digital remittance platform also enables e-wallets, remittance companies, and corporations to provide real-time, 24/7 payment services, advancing financial access across underserved communities. It generates the majority of its geographic revenue from Malaysia.

Share on Social Networks: